Healthcare / BiotechnologyParis
$3.55
-0.19 (-5.08%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-3.4M · quality 59.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$51M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-103.5%
↓Gross Margin
N/A
•Debt/Equity
0.99
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.36x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-3.0M · FCF $-1.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-3.0M | $-3.0M | $-1.8M | $-6.8M | $-6.6M |
| EBITDA | $-3.8M | $-3.8M | $-2.5M | $-7.3M | $-6.0M |
| EPS | — | — | -0.22 | -0.87 | -1.24 |
| Balance Sheet | |||||
| Debt/Equity | 0.99 | 0.99 | -1.73 | 1.64 | 0.85 |
| Current Ratio | 2.35 | 2.35 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.1M | $-1.1M | $-3.4M | $-6.4M | $-5.4M |
| Returns | |||||
| ROE | -103.5% | -103.5% | 106.5% | -307.4% | -114.7% |
| Valuation | |||||
| P/B | 16.84 | 16.84 | — | 3.94 | 1.83 |
| Growth & Yield | |||||
| EPS Growth | — | — | 75.0% | 29.3% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+266.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.22 → n/d
Residual
+266.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.